Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares of the company's stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Pushkal Garg also recently made the following trade(s):
- On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.
Alnylam Pharmaceuticals Stock Up 0.1 %
Shares of ALNY opened at $245.44 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a market capitalization of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32. The stock has a 50 day moving average price of $267.01 and a 200 day moving average price of $248.16.
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Biden broke it... Now Trump is going to fix it.
Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same period last year, the firm earned $1.15 EPS. The business's quarterly revenue was down 33.3% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Souders Financial Advisors boosted its stake in Alnylam Pharmaceuticals by 1.0% during the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company's stock worth $853,000 after buying an additional 36 shares during the last quarter. Huntington National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. SYM FINANCIAL Corp lifted its stake in shares of Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 55 shares during the last quarter. Lindbrook Capital LLC lifted its stake in shares of Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 57 shares during the last quarter. Finally, V Square Quantitative Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company's stock valued at $81,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Wolfe Research downgraded Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Chardan Capital reiterated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $298.09.
Read Our Latest Analysis on ALNY
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
